25 February 2022 - The TGA has updated its list of applications for new medicines or new uses for existing medicines that are currently under evaluation.

17 new applications were accepted for evaluation in January.  New applications of note are:

• Baricitinib (Olumiant, Eli Lilly) - new indication (alopecia areata)
• Maribavir (Livtencity, Takeda) - new anti-viral
• Patisiran sodium (Onpattro, Alnylam Pharmaceuticals) - new gene therapy for patients with amyloidosis
• Pralsetinib (Gavreto, Roche) - three discrete applications
• Tirzepatide (Mounjaro, Eli LIlly) - new medicine for patients with type 2 diabetes mellitus

Read TGA News